KR20010021682A - 녹내장 치료제로서 부작용이 없는 프로스타글란딘 유도체 - Google Patents

녹내장 치료제로서 부작용이 없는 프로스타글란딘 유도체 Download PDF

Info

Publication number
KR20010021682A
KR20010021682A KR1020007000240A KR20007000240A KR20010021682A KR 20010021682 A KR20010021682 A KR 20010021682A KR 1020007000240 A KR1020007000240 A KR 1020007000240A KR 20007000240 A KR20007000240 A KR 20007000240A KR 20010021682 A KR20010021682 A KR 20010021682A
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
prostaglandin
aryl
pge
Prior art date
Application number
KR1020007000240A
Other languages
English (en)
Korean (ko)
Inventor
스체른스찬쯔요한
레술바흐람
레이크스타판
Original Assignee
존 헤덴스트룀
파마시아 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20010021682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 존 헤덴스트룀, 파마시아 에이비 filed Critical 존 헤덴스트룀
Publication of KR20010021682A publication Critical patent/KR20010021682A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020007000240A 1997-07-11 1998-07-10 녹내장 치료제로서 부작용이 없는 프로스타글란딘 유도체 KR20010021682A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702706-4 1997-07-11
SE9702706A SE9702706D0 (sv) 1997-07-11 1997-07-11 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
PCT/SE1998/001368 WO1999002165A1 (en) 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Publications (1)

Publication Number Publication Date
KR20010021682A true KR20010021682A (ko) 2001-03-15

Family

ID=20407743

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007000240A KR20010021682A (ko) 1997-07-11 1998-07-10 녹내장 치료제로서 부작용이 없는 프로스타글란딘 유도체

Country Status (19)

Country Link
EP (1) EP1014991A1 (is)
JP (1) JP2002509543A (is)
KR (1) KR20010021682A (is)
CN (1) CN1169528C (is)
AU (1) AU739828B2 (is)
BR (1) BR9815501A (is)
CA (1) CA2294779A1 (is)
HK (1) HK1029942A1 (is)
HU (1) HUP0003106A3 (is)
IL (1) IL133871A (is)
IS (1) IS5333A (is)
NO (1) NO20000062D0 (is)
NZ (1) NZ501834A (is)
PL (1) PL337940A1 (is)
RU (1) RU2207858C2 (is)
SE (1) SE9702706D0 (is)
SK (1) SK183499A3 (is)
TR (1) TR200000008T2 (is)
WO (1) WO1999002165A1 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
GB0112699D0 (en) 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
AU2003299137A1 (en) * 2002-09-16 2004-04-23 Texas Tech University System Inhibition of metallo-beta-lactamase
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PL212658B1 (pl) * 2005-04-18 2012-11-30 Inst Farmaceutyczny Sposób otrzymywania pochodnych 13,14-dihydro-PGF<sub>2</sub><sub>α</sub>
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
JPWO2009133863A1 (ja) 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
AU2009354014B2 (en) * 2009-10-16 2014-08-28 Cayman Chemical Company, Incorporated Process for the preparation of F-series prostaglandins
KR102070567B1 (ko) 2012-03-28 2020-01-29 메르크 파텐트 게엠베하 바이시클릭 피라지논 유도체
JP2012246301A (ja) * 2012-08-10 2012-12-13 Cayman Chemical Co Inc Ｆ系プロスタグランジン類を調製する方法
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
WO1994008585A1 (en) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Also Published As

Publication number Publication date
JP2002509543A (ja) 2002-03-26
AU739828B2 (en) 2001-10-18
NO20000062L (no) 2000-01-06
TR200000008T2 (tr) 2000-05-22
WO1999002165A1 (en) 1999-01-21
BR9815501A (pt) 2001-07-17
RU2207858C2 (ru) 2003-07-10
SE9702706D0 (sv) 1997-07-11
NO20000062D0 (no) 2000-01-06
EP1014991A1 (en) 2000-07-05
PL337940A1 (en) 2000-09-11
IL133871A0 (en) 2001-04-30
IL133871A (en) 2004-09-27
HUP0003106A3 (en) 2002-12-28
CN1169528C (zh) 2004-10-06
CA2294779A1 (en) 1999-01-21
IS5333A (is) 2000-01-07
AU8368398A (en) 1999-02-08
CN1262623A (zh) 2000-08-09
SK183499A3 (en) 2000-07-11
HK1029942A1 (en) 2001-04-20
HUP0003106A2 (hu) 2001-01-29
NZ501834A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
KR20010021682A (ko) 녹내장 치료제로서 부작용이 없는 프로스타글란딘 유도체
FI92690C (fi) Menetelmä farmakologisesti aktiivisten 13,14-dihydro-17-fenyyli-18,19,20-trinor-PGF2 -alkyyliestereiden valmistamiseksi
US6232344B1 (en) 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension
US20010023258A1 (en) Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US20030181493A1 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
KR20070107065A (ko) 중추 신경계 질환 치료를 위한 방법 및 조성물
US6172109B1 (en) 13-Thia prostaglandins for use in glaucoma therapy
EP0344235A1 (en) PROSTAGLANDIN DERIVATIVES FOR TREATING GLAUCOMA OR EYE PRESSURE.
KR100195430B1 (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
EP1140108B1 (en) Method and composition for treatment of female sexual dysfunction
KR20000053228A (ko) 안압강하제로서의 프로스타글란딘의 시스-δ⁴ 유사체
CZ20023092A3 (cs) Farmaceutický prostředek vhodný pro dlouhodobou léčbu nebo profylaktické ošetření oční hypertenze a glakomu
CZ200084A3 (cs) Prostaglandinové deriváty pro léčení glaukomu, bez vedlejších účinků
DK176053B1 (da) Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk
MXPA00000403A (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
NZ230619A (en) Ophthalmological composition comprising a prostaglandin derivative for treating glaucoma
EP1300151A2 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ZA200207140B (en) Treatment of ocular hypertension and glaucoma.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application